Key result
VEGF inhibitors combined with immunotherapy enhance T-lymphocyte action against tumor cells.
Answers are grounded in this paper and cite their sources.
This review highlights the crosstalk between VEGFs and the immune system, suggesting potential for combining VEGF inhibitors with immunotherapies.
The vascular endothelial growth factor (VEGF) family includes key mediators of vasculogenesis and angiogenesis. VEGFs are secreted by various cells of epithelial and mesenchymal origin and by some immune cells in response to physiological and pathological stimuli. In addition, immune cells express VEGF receptors and/or coreceptors and can respond to VEGFs in an autocrine or paracrine manner. This immunological role of VEGFs has opened the possibility to use the VEGF inhibitors already developed to inhibit tumor angiogenesis also in combination approaches with different immunotherapies to enhance the action of effector T lymphocytes against tumor cells. This review aims at analyzing the current knowledge on the crosstalk between VEGFs and the immune system and at highlighting those aspects that still need to be further investigated.
No takes yet. Share an insight, caveat, or question.
Failla et al. (2024) conducted a review in Crosstalk between VEGFs and the immune system. This review highlights the immunological role of VEGFs and the potential of combining VEGF inhibitors with immunotherapies to enhance T lymphocyte action against tumor cells.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: